While JAK2 V617F excludes MDS/MPN-SF3B1-T diagnosis (5, 6), our patient’s rare R683G variant, lacks canonical MPN-driving potency, maintains diagnostic eligibility per 2022 WHO technical notes (5). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.